Stock Ratings / Health Care / PBM / financials

COCP (42) KYNB (44) MCRB (54) QNRX (48) ⌘ Pro Terminal →

Psyence Biomedical Ltd. (PBM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.61 +6.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.64

Psyence Biomedical Ltd. (PBM) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $19.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.64 (+0.92%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY PBM SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 35.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$4.97-15.1% Next Q

Q2 (-2Q)

Grade B-$4.22-1.4% Next Q

Q3 (-1Q)

Grade C+$4.16-13.2% Next Q

Current

Grade C-$3.61+0.5% Hist 90D α

Trajectory: B- (69) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PBM Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, PBM faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.82) or 200D SMA ($4.21) invalidates the momentum regime and cuts Target Base ($3.66) toward Bear Floor ($2.85).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PBM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How PBM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$537.3K (0% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PBM)

✓Walkthrough of PBM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PBM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -45.22%▲ ASCENDING TRIANGLE

2026-10-30O $3.51H $3.64L $3.28C $3.61VOL 46.6K

SUP: $2.70SMA50: $4.82SMA200: $4.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBM Butterfly Map → + Track PBM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PBM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PBM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBM)

Health Care Rank #197 of 1016 ⚔️ COCP vs PBM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBM vs. COCP, KYNB, MCRB, QNRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Psyence Biomedical Ltd. (PBM) ranks #197 by composite RQD confidence (61/100, grade C-) and #837 by equity capitalization ($19.2M). Within this direct 5-issuer industry benchmark cohort, PBM leads on earnings valuation at N/A trailing P/E, while COCP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PBM currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PBM ACTIVE Psyence Biomedical Ltd.	C-	61/100	—	—	—	+6.18%	$19.2M	Benchmark Subject
COCP Cocrystal Pharma Inc.	D-	42/100	—	—	-35.0%	-1.01%	$18.9M	/cocp-vs-pbm →
KYNB Kyntra Bio Inc.	D	44/100	—	91.4%	-35.0%	-1.48%	$18.8M	/kynb-vs-pbm →
MCRB Seres Therapeutics Inc.	D+	54/100	—	—	-35.0%	+8.94%	$19.6M	/mcrb-vs-pbm →
QNRX Quoin Pharmaceuticals Ltd.	D	48/100	—	—	-35.0%	+0.97%	$19.9M	/qnrx-vs-pbm →

2. PBM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Psyence Biomedical Ltd. (PBM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $19.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. PBM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Psyence Biomedical Ltd. (NASDAQ: PBM) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $3.61 (+6.18% 1D, market cap $19.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PBM ranks #197 in composite RQD confidence.

How does PBM compare to COCP and KYNB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBM carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COCP (Cocrystal Pharma Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $18.9M) and KYNB (Kyntra Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, PBM leads on earnings multiple (N/A) while COCP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PBM?

For Psyence Biomedical Ltd. (PBM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #197 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PBM trading relative to its 50-day, 200-day, and 52-week technical levels?

PBM last traded at $3.61 (+6.18% on volume of 62,146 shares), positioning the stock -25.10% below its 50-day simple moving average ($4.82) and -14.25% below its 200-day simple moving average ($4.21). Across its 52-week range of $1.92 to $122.85, PBM sits at the 1.4% percentile with a 14-day RSI of 35.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.16 to $4.06).

PBM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Psyence Biomedical Ltd. (PBM)?

In Trailing 12 Months, PBM converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $537304 in free cash flow (0% FCF margin).

Direct Sub-Reports: PBM RQD Cockpit PBM 12M Forecast PBM Earnings & Move PBM Dividends & DRIP PBM Insiders & 13F PBM Whale Options PBM Profit Sankey PBM News & Why